Trial · NCT07888829
G-CSF In Neonatal Sepsis With Neutropenia
NCT07888829, Not applicable, Not yet recruiting, University of Health Sciences Lahore
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. G-CSF In Neonatal Sepsis With Neutropenia. Trials, record NCT07888829. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07888829
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- G-CSF In Neonatal Sepsis With Neutropenia
- NCT number
- NCT07888829
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 52 participants, estimated
- Lead sponsor
- University of Health Sciences Lahore
- Conditions
- Neonatal Sepsis, Neutropenia
- Interventions
- Granulocyte-colony stimulating factor (G-CSF), Standard Sepsis Management
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mortality | From enrollment until discharge or death, within the first 28 days of life | Mortality among neonates with sepsis and neutropenia will be compared between the intervention group receiving G-CSF plus standard sepsis management and the control group receiving standard sepsis management alone. |
| Secondary | Change in Absolute Neutrophil Count (ANC) | Baseline through Day 3 (daily assessments during the 3-day treatment period) | The absolute neutrophil count (ANC) will be measured before and after G-CSF administration to assess improvement in neutrophil count among neonates with sepsis and neutropenia. |
| Secondary | Duration of Neutropenia | From enrollment through hospital discharge, up to 28 days of life | Duration of neutropenia will be assessed in neonates with sepsis and neutropenia and compared between the intervention and control groups. Neutropenia is defined as an absolute neutrophil count below 1500/µL. |
| Secondary | Duration of Hospital Stay | From enrollment through hospital discharge, up to 28 days of life | The duration of hospitalization will be recorded for neonates in the intervention and control groups and compared to determine whether addition of G-CSF is associated with a shorter hospital stay. |
| Secondary | Frequency of Healthcare-Associated Infections | From enrollment through hospital discharge, up to 28 days of life | The frequency of healthcare-associated infections will be recorded and compared between the intervention and control groups. Healthcare-associated infection is defined as a new episode of infection occurring ≥72 hours after G-CSF administration in a neonate initially admitted with sepsis and neutropenia. |
| Secondary | Catheter-Associated Urinary Tract Infection (CAUTI) | From enrollment through hospital discharge, up to 28 days of life | The occurrence of catheter-associated urinary tract infection will be recorded in neonates in both study groups and compared between the intervention and control groups during hospitalization. |
| Secondary | Central Line-Associated Bloodstream Infection (CLABSI) | From enrollment through hospital discharge, up to 28 days of life | The occurrence of central line-associated bloodstream infection will be recorded in neonates in both study groups and compared between the intervention and control groups during hospitalization. |
| Secondary | Ventilator-Associated Pneumonia (VAP) | From enrollment through hospital discharge, up to 28 days of life | The occurrence of ventilator-associated pneumonia will be recorded in neonates in both study groups and compared between the intervention and control groups during hospitalization. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07888829
GET https://conductscience.org/api/trials/v1/NCT07888829/registered